It is quite obvious that apelins that remain stable during enzymatic hydrolysis with a long half-life have the greatest prospects for clinical use in the treatment of stroke, acute myocardial infarction, and in the prevention of adverse myocardial remodeling. Here, APLN is linked to Stroke.